Fertility challenges are often linked to hormones, ovulation problems, or
reproductive anatomy. However, according to Dr Marina OBGYN, modern research is
revealing another important factor behind infertility in many women: chronic
inflammation and immune system imbalance.

One treatment gaining attention in reproductive medicine is Low-Dose
Naltrexone, commonly called LDN. Originally developed for addiction treatment,
naltrexone works very differently when used in extremely small doses.
Researchers and fertility specialists are now studying how LDN may help support
reproductive health in women with conditions such as PCOS, endometriosis, and
recurrent implantation failure.

Dr Marina OBGYN explains that low-dose naltrexone may help regulate immune
activity, reduce inflammation, and increase the body’s natural endorphin
production. This is important because both PCOS and endometriosis are
increasingly recognized as inflammatory conditions rather than simple hormone
disorders alone.
Women with PCOS often experience irregular
cycles, insulin resistance, hormonal imbalance, and difficulty ovulating.
Chronic inflammation may interfere with healthy egg development and fertility.
Early studies suggest that LDN may support more regular ovulation, improve
hormone communication between the brain and ovaries, and create a healthier
reproductive environment.

Endometriosis is another condition where inflammation plays a major role. In
endometriosis, tissue similar to the uterine lining grows outside the uterus,
causing pain, pelvic inflammation, and fertility complications. According to Dr
Marina OBGYN, this inflammatory environment may damage eggs, interfere with
sperm function, and reduce successful embryo implantation.

Low-dose naltrexone may help calm immune cells and reduce inflammatory
activity within the pelvis. Some patients using LDN have reported reduced
pelvic pain and improved overall reproductive health. Ongoing clinical research
continues to explore how this therapy may support fertility treatment outcomes.

Another promising area of study involves implantation support during IVF.
Recent research suggests that women experiencing repeated implantation failure
may benefit from LDN because it may help improve uterine lining thickness and
balance immune responses that affect embryo implantation.

Dr Marina OBGYN emphasizes that LDN is not a replacement for fertility
medications, IVF, or surgical treatment. Instead, it may work alongside
conventional therapies by improving the body’s internal environment and
reducing chronic inflammation that interferes with conception.

One reason LDN is attracting attention is because it is generally well
tolerated, non-hormonal, low-cost, and associated with relatively few side
effects. Some women experience mild sleep changes or vivid dreams initially,
but serious complications are considered uncommon.

Ultimately, fertility medicine is moving toward more personalized and
restorative approaches. According to Dr
Marina OBGYN, treatments like low-dose naltrexone represent a growing focus
on supporting the body’s natural healing systems rather than simply overriding
reproductive function.

By reducing inflammation and improving immune balance, LDN may offer new
hope for women struggling with PCOS, endometriosis, and fertility challenges in
the modern world.